The short version of Lipodystrophy fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-20 and is reviewed periodically as new material appears.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
A drinking water sample from a well near the site had levels of contamination 500 times higher than the maximum limits recommended by the World Health Organization. In 2009, the Centre for Science and Environment, a Delhi-based pollution monitoring lab, released test results showing pesticide groundwater contamination up to three kilometres from the factory. Also in 2009, the BBC took a water sample from a frequently used hand pump, located just north of the plant. The sample, tested in UK, was found to contain 1,000 times the World Health Organization's recommended maximum amount of carbon tetrachloride, which causes liver and kidney damage, and is "possibly carcinogenic to humans". In 2010, a British photojournalist ventured into the abandoned UCIL factory to investigate allegations of abandoned, leaking toxins. He was hospitalized in Bhopal for a week after he was exposed to chemicals. Doctors at the Sambhavna Clinic treated him with oxygen, painkillers and anti-inflammatories following a severe respiratory reaction to toxic dust inside the factory. In October 2011, the Institute of Environmental Management and Assessment published an article and video by two British environmental scientists, showing the current state of the plant, landfill and solar evaporation ponds and calling for renewed international efforts to provide the necessary skills to clean up the site and contaminated groundwater. On December 3, 2024, the 40th anniversary of the incident, Madhya Pradesh High Court ruled that the site must be cleaned up in the next month.
=== Chymotrypsin-like === The S1 pocket of chymotrypsin-like enzymes is more hydrophobic than in trypsin-like proteases. This results in a specificity for medium to large sized hydrophobic residues, such as tyrosine, phenylalanine and tryptophan.
The scientific name Asteroidea was given to starfish by the French zoologist de Blainville in 1830. It is derived from the Greek aster, ἀστήρ (a star) and the Greek eidos, εἶδος (form, likeness, appearance). Starfish are included in the subphylum Asterozoa along with brittle and basket stars (order Ophiuroidea), the characteristics of which include a star-shaped body as adults, with multiple arms surrounding central disc. The arms of asteroids are skeletally connected to the disc by ossicles in the body wall while ophiuroids have clearly demarcated arms. The starfish are a large and diverse class with over 1,900 living species. There are seven extant orders: Brisingida, Forcipulatida, Notomyotida, Paxillosida, Spinulosida, Valvatida and Velatida. Living asteroids, the Neoasteroidea, are distinct from their forerunners in the Paleozoic. Their classification has changed little but there is debate in regards to Paxillosida. The deep-water sea daisies, though clearly Asteroidea and currently included in Velatida, do not fit easily in any accepted lineage. Phylogenetic data suggests that they may be a sister group, the Concentricycloidea, to the Neoasteroidea, or that the Velatida themselves may be a sister group.
== Applications == TCEP is often used as a reducing agent to break disulfide bonds within and between proteins as a preparatory step for gel electrophoresis. Compared to the other two most common agents used for this purpose (dithiothreitol and β-mercaptoethanol), TCEP has the advantages of being odorless, a more powerful reducing agent, an irreversible reducing agent (in the sense that TCEP does not regenerate—the end product of TCEP-mediated disulfide cleavage is in fact two free thiols/cysteines), more hydrophilic, and more resistant to oxidation in air. It also does not reduce metals used in immobilized metal affinity chromatography. TCEP is particularly useful when labeling cysteine residues with maleimides. TCEP can keep the cysteines from forming di-sulfide bonds and, unlike dithiothreitol and β-mercaptoethanol, it will not react as readily with the maleimide. However, TCEP has been reported to react with maleimide under certain conditions. TCEP is also used in the tissue homogenization process for RNA isolation. For Ultraviolet–visible spectroscopy applications, TCEP is useful when it is important to avoid interfering absorbance from 250 to 285 nanometers which can occur with dithiothreitol. Dithiothreitol will slowly over time absorb more and more light in this spectrum as various redox reactions occur.
== Chemical modifications == Creating chemically stable short oligonucleotides was the earliest challenge in developing ASO therapies. Naturally occurring oligonucleotides are easily degraded by nucleases, an enzyme that cleaves nucleotides and is ample in every cell type. Short oligonucleotide sequences also have weak intrinsic binding affinities, which contributes to their degradation in vivo.
Sources: en.wikipedia.org
Hydrolysis of proteins with broad specificity. Generally favours hydrophobic residues in P1 and P1', but also accepts Lys in P1, which leads to activation of trypsinogen. Does not clot milk This enzyme is found in a variety of Aspergillus species.
Calcium dobesilate is a vasoprotective. It is the calcium salt of dobesilic acid. It is a synthetic molecule with the ability to reduce capillary permeability in the body. In Switzerland the drug is sold by the pharmaceutical company OM Pharma under the trade name of Doxium in capsules containing 500 mg of active ingredient.
=== Mechanism of action === Avasimibe is a potent activator of the pregnane X receptor and, consequently, an indirect inducer of CYP3A4 and P-glycoprotein, as well as a potent inhibitor of several cytochrome P450 isoenzymes, including CYP1A2, CYP2C9, and CYP2C19; its spectrum of CYP induction and inhibition is similar to that of rifampicin.
In fact, the variables were nearly too widespread to track, including: spontaneous fermentation, the type of vessels used, environmental conditions, and the apple varieties. Refinements came much later when cider became a commercial product and the process was better understood. However, since there is growing popularity in ciders, the production of speciality styles has begun to increase. Cider alcohol content varies from 1.2% to 8.5% ABV or more in traditional English ciders, and 2.5% to 12% in continental ciders. In UK law, it must contain at least 35% apple juice (fresh or from concentrate), although CAMRA (the Campaign for Real Ale) says that "real cider" must be at least 90% fresh apple juice. In the US, there is a 50% minimum. In France, cider must be made solely from apples. Perry is a similar product to cider made by fermenting pear juice. Cider can be distilled into fruit brandy. In the US and Canada, varieties of alcoholic cider are often called "hard cider" to distinguish it from non-alcoholic apple cider or "sweet cider", also made from apples at cider mills. In Canada, cider cannot contain less than 2.5% or over 13% absolute alcohol by volume. In addition to the UK and its former colonies, cider is popular in France (particularly Normandy and Brittany), Portugal (mainly in Minho and Madeira), northern Italy (specifically Friuli), and northern Spain (specifically Asturias, Basque Country). Due to their fermentation, ciders can be thought of as a fruit wine of apples, though exact definitions of either beverage can vary by culture.
Sources: en.wikipedia.org
During the COVID-19 pandemic, Michelle Bachelet, the United Nations High Commissioner for Human Rights, and some members of the United States Congress asked the United States to suspend its sanctions regimes as a way to help alleviate the pandemic's impact on people in sanctioned countries. Members of Congress who argued for suspension included Bernie Sanders, Alexandria Ocasio-Cortez, and Ilhan Omar. According to a 2024 analysis by The Washington Post, 60% of low-income countries were under some form of U.S. financial sanction, and the U.S. imposes three times as many sanctions as any other country or international body.
UPMC currently operates 40 academic, community, and specialty hospitals with more than 8,000 licensed beds, 600 clinical locations including outpatient sites and doctors' offices, and outpatient sites; over 50 cancer center locations; more than 70 facilities for physical, occupational, speech and specialty therapies; and 20 retirement and long-term care sites.
PyBOP (benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate) is a reagent used to prepare amides from carboxylic acids and amines in the context of peptide synthesis. It can be prepared from 1-hydroxybenzotriazole and a chlorophosphonium reagent under basic conditions. It is a substitute for the BOP reagent that avoids the formation of the carcinogenic waste product HMPA. Thermal hazard analysis by differential scanning calorimetry (DSC) shows PyBOP is potentially explosive.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.